The STS/ACC Transcatheter Valve Therapy (STS/ACC TVT) national registry
was initiated in 2011, and captures data on all commercial transcatheter
aortic valve replacement procedures performed in the United States.
45,938 CoreValve, EvolutR, and EvolutPRO Cases
in TVT Registry
(Jan 2014-June 2018)
Bicuspid Aortic Valve Morphology
N=1,232
CoreValve
23, 26, 29, or 31 mm
N=319
EvolutR
23, 26, 29, or 34 mm
N=677
EvolutPRO
23, 26, or 29 mm
N=236
All Non-Bicuspid
Cases
N=44,706
•valve in valve
•native tricuspid
aortic valve
•aortic insufficiency
•other
44,4
8,9
44,6
9,0
45,9
8,7
0
10
20
30
40
50
60
70
Baseline 30 Days
CoreValveEvolut REvolut PRO
47,7%
62,8%
68,1%
29,2%
29,3%
30,6%
20,5%
7,5% 1,3%
2,6% 0,4%
0%
20%
40%
60%
80%
100%
CoreValve
(N=195)
Evolut R
(N=481)
Evolut PRO
(N=160)
30
-Day Total Aortic Regurgitation
(% of Patients)
Severe
Moderate
Mild
None / Trace
p<0.01 p=0.22
Autoexpandible Corevalve Evolut